Please assess the completion status of the following clinical trial:

Trial Title: Scleroderma: Cyclophosphamide or Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe systemic sclerosis (SSc) as defined by the American College of Rheumatology (ACR);~* SSc, including extensive skin and internal organ involvement involving either the lungs or the kidneys, that threatens participant's life; and~* Willingness to use accepted methods of contraception for at least 15 months after starting study treatment.~Exclusion Criteria:~* Lung, heart, liver, or kidney impairment that would interfere with the study or compromise participant's survival;~* Active blood vessel dilation in the stomach (Active Gastric Antral Vascular Ectasia/GAVE, also known as watermelon stomach). Patients found to have this disorder at study screening can receive treatment outside the study and then be re-screened. For more information about this study criterion, refer to the study protocol.~* Previous treatment with cyclophosphamide, as defined by: a) prior IV cyclophosphamide administration for more than 6 months OR a total cumulative IV dose greater than 3 g/m\^2; b) prior oral cyclophosphamide administration for more than 4 months, regardless of dose; or c) combination of prior oral and IV cyclophosphamide administration for more than 6 months, independent of dose.~* Steroid therapy at doses of greater than 10 mg/day, or more than 2 pulses for concurrent illnesses within prior 12 months;~* Unwillingness or inability to discontinue certain disease-modifying antirheumatic drugs (DMARDs) for the treatment of SSc;~* Presence of clinically significant rheumatic diseases other than scleroderma requiring significant immunosuppression;~* Any active uncontrolled infection that would interfere with high-dose therapy or pulse cyclophosphamide regimens:~  * Hepatitis B virus infected~ * Hepatitis C virus infected or~ * HIV infected.~* Blood abnormalities;~* Diagnosis of cancer within 2 years prior to study entry. Participants with adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ are not excluded.~* Other comorbid illnesses with an estimated life expectancy of less than 5 years;~* Defective formation of bone marrow cells (myelodysplasia);~* Uncontrolled hypertension;~* History of hypersensitivity to murine or Escherichia coli (e.g., E. coli) proteins; History of noncompliance with prior medical care;~* History of substance abuse within 5 years prior to study entry; or~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- mHSCT (Type: EXPERIMENTAL): Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
- cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m\^2, followed by 11 doses of 750 mg/m\^2).

Based on this trial design, predict the completion outcome and termination type (if applicable).